Literature DB >> 7616004

Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis.

J M Hanifin1, S C Chan.   

Abstract

The immunologic aberrations associated with atopic dermatitis include the paradox of reduced cell-mediated immune responses in the setting of increased cell-mediated immunity features that resemble allergic contact dermatitis. In this review, we present evidence that abnormalities in monocytes and Langerhans cells alter the function of T-helper-cell subpopulations to cause the immunologic defects associated with atopic dermatitis. Increased monocyte prostaglandin E2 production inhibits Th1 responses, accentuating interleukin (IL)-4 secretion by Th2 cells. Elevated prostaglandin E2 secretion correlates with abnormally increased cyclic adenosine monophosphate-phosphodiesterase activity in monocytes and this, along with other defective inflammatory cell responses, can be normalized in vitro by phosphodiesterase inhibitors. It appears that in addition to prostaglandin E2, IL-10 acts to regulate the balance between Th1 and Th2 functional responses accounting for many atopic features, including increased IL-4, IL-5, and IL-6 production by T cells; increased IgE synthesis; decreased interferon-gamma production; and impaired cell-mediated immune responses. All of these abnormalities can be related to increased phosphodiesterase activity in atopic monocytes, and inhibition of this key enzyme appears to reverse atopic dermatitis inflammatory abnormalities in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7616004     DOI: 10.1111/1523-1747.ep12316116

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  12 in total

1.  Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D.

Authors:  G Hansen; S Jin; D T Umetsu; M Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  The high-affinity IgE receptor (FcepsilonRI) blocks apoptosis in normal human monocytes.

Authors:  N Katoh; S Kraft; J H Wessendorf; T Bieber
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

Review 3.  The spectrum of cutaneous patch-test reactions in patients with atopic dermatitis.

Authors:  J M Hanifin; P A Klas
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

4.  A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.

Authors:  Aman Samrao; Trista M Berry; Renato Goreshi; Eric L Simpson
Journal:  Arch Dermatol       Date:  2012-08

Review 5.  The genetics of atopic dermatitis.

Authors:  Yin-Hsiu Chien; Wuh-Liang Hwu; Bor-Luen Chiang
Journal:  Clin Rev Allergy Immunol       Date:  2007-12       Impact factor: 8.667

Review 6.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Long-term Efficacy of Intravenous Immunoglobulin Therapy for Moderate to Severe Childhood Atopic Dermatitis.

Authors:  Sue-Jung Jee; Joo-Hwa Kim; Hey-Sung Baek; Ha-Baik Lee; Jae-Won Oh
Journal:  Allergy Asthma Immunol Res       Date:  2011-02-14       Impact factor: 5.764

8.  Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects.

Authors:  Gail M Gauvreau; Louis-Philippe Boulet; Christine Schmid-Wirlitsch; Johanne Côté; Mylinh Duong; Kieran J Killian; Joanne Milot; Francine Deschesnes; Tara Strinich; Richard M Watson; Dirk Bredenbröker; Paul M O'Byrne
Journal:  Respir Res       Date:  2011-10-26

9.  New and Emerging Therapies for Pediatric Atopic Dermatitis.

Authors:  Henry L Nguyen; Katelyn R Anderson; Megha M Tollefson
Journal:  Paediatr Drugs       Date:  2019-08       Impact factor: 3.930

Review 10.  Role of macrophages in the pathogenesis of atopic dermatitis.

Authors:  Sadaf Kasraie; Thomas Werfel
Journal:  Mediators Inflamm       Date:  2013-03-04       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.